Heart Failure Monitoring System Proven to Reduce Hospital Admissionss Receives CMS Approval
St. Paul, MN - St. Jude Medical, Inc. today announced that the Center for Medicare and Medicaid Services (CMS) has approved a New Technology Add-on Payment (NTAP) for the CardioMEMS™ HF System. The CardioMEMS HF System is the first and only U.S. Food and Drug Administration approved heart failure (HF) monitoring device that has been proven to significantly reduce hospital admissions when used by physicians to manage heart failure. The NTAP program, which recognizes new technologies that provide substantial clinical improvement over already available therapies, is designed to support timely access to innovative technologies for Medicare beneficiaries.
“We are pleased CMS recognizes the substantial clinical benefit provided by the CardioMEMS HF System,” said Eric S. Fain, M.D., group president of St. Jude Medical. “This favorable decision helps ensure that Medicare patients have access to this innovative technology as we introduce CardioMEMS as a new treatment paradigm to proactively manage heart failure, improve patient outcomes and reduce hospital admissions.” Continue>
Posted in: News Briefs | July 20, 2013
Posted in: News Briefs | January 10, 2017